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p-Sulfonic acid calix[4]areneAbstract Fourteen phthalazine-triones bearing different substituents at C-4 position were synthe-
sized through multicomponent reactions (MCR) by using phthalhydrazide, dimedone and diferent
aldehydes as starting materials, p-sulfonic acid calix[4]arene as catalyst and ethyl lactate as solvent
under microwave irradiation. Compounds 7–16 were obtained in excellent to moderate yields (94–
51%) in only 10 min of reaction using this methodology. The antiproliferative activity against can-
cer cells was disclosed, for the ﬁrst time, for synthesized compounds. The capacity of all compounds
to inhibit cancer cells growth was dependent on the histological origin of cells. Compound 20 was
active against more than one strain.
 2016 The Authors. Production and hosting by Elsevier B.V. on behalf of King Saud University. This is
an open access article under theCCBY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).t human
2 Y.F. Rego et al.1. Introduction
Phthalazine derivatives (Fig. 1) are nitrogen heterocycle compounds
constituting a bridgehead hydrazine (Khurana and Magoo, 2009).
This class of compounds has been shown to possess a range of biolog-
ical and pharmacological properties such as anticonvulsant (Grasso
et al., 2000), cardiotonic (Nomoto et al., 1990), vasorelaxant
(Watanabe et al., 1998) and antiproliferative (Scott et al., 2007), as well
as their unique luminescence properties (Wu et al., 2009).
The phthalazine 2 (Fig. 1) was described by Grasso and coworkers
(Grasso et al., 2000) as a potent anticonvulsant agent, while compound
1-chloro-4-(3-chloro-4-methoxybenzylamino)-6-phthalazine carboni-
trile, 3, (Fig. 1) has vasorelaxant activity via inhibition of cyclic nucleo-
tide phosphodiesterase 5 (PDE5). This compound was able to inhibit
the activity of PDE5 at level of 50% when used at only 3.5 nM
(Watanabe et al., 1998). Antiproliferative activities were also described
for phthalazines, being the most notable example is vatalanib (4), an
inhibitor of vascular growth factor, which is in clinical phase III for
metastatic colorectal cancer (Fig. 1) (Scott et al., 2007). Despite the
diverse biological proﬁle exhibited by phthalazines derivatives,
phthalazine-triones have their biological activities poorly explored.
In the only reports, Berber et al., demonstrated that urea- and
b-lactam-phthalazine-trione derivatives inhibit the human carbon
anhydrase (Berber et al., 2013, 2015).
These compounds can be obtained using multicomponent reactions
(MCR). This approach is based on three-component condensations
with aldehydes, 5,5-dimethylcyclohexane-1,3-dione (dimedone) and
2,3-dihydro-1,4-phthalazinedione (phthalhydrazide) and employs dif-
ferent catalysts such as p-toluenesulfonic acid (PTSA) (Sayyaﬁ et al.,
2008), Ce(SO4)24H2O (Mosaddegh and Hassankhani, 2011), dode-
cylphosphonic acid (DPA) (Kidwai et al., 2012), camphorsulfonic acid
(CSA) (Shukla et al., 2011), silica supported polyphosphoric acid
(Shaterian et al., 2009) and N-halosulfonamides (Ghorbani-Vaghei
et al., 2011). However, so far there are no reports of the use of calix
[n]arenes as catalysts in the synthesis of phthalazine derivatives.
Calix[n]arenes are macrocyclic cavity-shaped molecules obtained
from the ortho-condensation of para-substituted phenols and
formaldehyde in a basic medium (de Fa´tima et al., 2009; Simoes
et al., 2012). Over the last few decades, these supramolecules haveN
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as molecular hosts and organocatalysts (Gutsche, 2008; Vareja˜o et al.,
2013). Among all of the calix[n]arenes known so far, p-sulfonic acid
calix[4]arene (5) and p-sulfonic acid calix[6]arene (6) (Fig. 2) have been
shown to be the most efﬁcient catalysts for different multicomponent
reactions (da Silva et al., 2011, 2015; Simo˜es et al., 2013, 2014).
Solvents are responsible for a large share of the environmental
impact of the production processes of the chemical industry and are
directly related to factors such as cost, safety and performance
(Capello et al., 2007). In this context, the search for ‘‘green solvents”
aims to reduce the environmental impact resulting from the use of sol-
vents in chemical production processes (Capello et al., 2007). These
solvents have been characterized for their low toxicity, easy biodegrad-
ability under environmental conditions, high boiling point and easy
recyclability after use (Capello et al., 2007). Ethyl lactate is a ‘‘green
solvent” derived from processing raw biomass material. This com-
pound is the ester of lactic acid, and some lactate esters are solvents
commonly used in the paints and coatings industry and have numerous
attractive advantages, including being 100% biodegradable, easy to
recycle, non-corrosive, non-carcinogenic and non-ozone depleting
(Pereira et al., 2011). Dimethyl and diethyl carbonate also have prop-
erties that can lead to them being considered ‘‘green solvents”, such as
their very low solubility in water, high boiling point and low vapor
pressure.
In this paper, we report a facile synthesis of 2H-indazolo[2,1-b]
phthalazine-trione derivatives by the microwave-assisted one-pot
three-component condensation of aromatic or aliphatic aldehydes, 5,
5-dimethylcyclohexane-1,3-dione and phthalhydrazide in the presence
of a catalytic amount of p-sulfonic acid calix[4]arene using ethanol,
ethyl lactate, dimethyl carbonate and diethyl carbonate as ‘‘green sol-
vents”. This procedure is very interesting because it combines a MCR
synthetic protocol using microwave irradiation in the presence of green
solvents. We also report the biological evaluation of fourteen
phthalazine-triones as inhibitors of cancer cells proliferation.
2. Materials and methods
All of the chemicals were obtained from commercially avail-
able sources and used without further puriﬁcation. MeltingN
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Calix[4]arene-assisted synthesis 3points (uncorrected) were determined on a Mettler FP 80 HT
apparatus. Infrared spectra were recorded on a Perkin Elmer
Spectrum One spectrometer (KBr). 1H and 13C NMR spectra
were recorded on a Bruker AVANCE DPX-200 spectrometer
in CDCl3 or DMSO-d6. High resolution mass spectra were
acquired on a Shimadzu LCMS-IT-TOF instrument. Single
crystal X-ray diffraction measurements were carried out on
an Oxford-Diffraction GEMINI-Ultra diffractometer
(LabCri-UFMG) using graphite-Enhance Source Mo Ka radi-
ation (k= 0.71073 A˚) at 150(2) K. The data collection, cell
reﬁnements, and data reduction were performed using the Cry-
sAlisPro software package (Oxford Diffraction, 2010). An
absorption correction based on a multi-scan method was
applied (Oxford Diffraction, 2010). The crystal structure was
solved by direct methods using SHELXS-97 (Sheldrick,
2008). A full-matrix least-squares reﬁnement procedure on F2
with anisotropic thermal parameters was carried on using
SHELXL (Sheldrick, 2008). Positional and anisotropic atomic
displacement parameters were reﬁned for all non-hydrogen
atoms. Hydrogen atoms were placed geometrically, and their
positional parameters were reﬁned using a riding model. PLA-
TON was used to prepare the molecular graphics (Spek, 2009).
2.1. General procedure for the synthesis of phthalazine-triones 7–
20
2,3-Dihydrophthalazine-1,4-dione (1.0 mmol), 5,5-dimethylcy
clohexane-1,3-dione (1.2 mmol), aldehyde (1.5 mmol) and
p-sulfonic acid calix[4]arene (1.5 mol%) were dissolved in
1 mL of ethyl lactate. The mixture was irradiated in a Dis-
coverCem reactor for 10 min at 130 C. The reaction was
cooled to room temperature and water was added. The mix-
ture was placed in a freezer at 20 C to form the precipitate.
The solid was isolated by ﬁltration and puriﬁed by chromatog-
raphy on a silica gel column using hexane/ethyl acetate as the
eluent to obtain the phthalazine-trione of interest.
2.1.1. 3,3-Dimethyl-13-phenyl-2,3,4,13-tetrahydro-1H-indazolo
[1,2-b]phthalazine-1,6,11-trione (7) (Sayyafi et al., 2008)
Yellow solid. mp: 189–190 C. IR (KBr) (mmax/cm1): 3086,
3026, 2960, 2926, 1666, 1628, 1600, 1468, 1420, 1358, 1314,
1268, 1168, 1142, 1100, 1082, 798, 702, 560. 1H NMR
(200 MHz, CDCl3): d 1.11 (bs, 6H, 2x CH3), 2.23 (bs, 2H,
CH2), 3.14 (d, 1H, J= 18.0 Hz, CH2), 3.33 (d, 1H,
J= 18.0 Hz, CH2), 6.34 (s, 1H, CH), 7.09–7.46 (m, 5H,
ArH), 7.66–7.85 (m, 2H, ArH), 8.08–8.36 (m, 2H, ArH); 13C
NMR (50 MHz, CDCl3): d 28.3 (CH3), 28.5 (CH3), 34.5 (C),
37.8 (CH2), 50.7 (CH2), 64.8 (CH), 118.4 (C), 127.0 (CH),
127.5 (CH), 127.8 (CH), 128.5 (CH), 128.7 (C), 128.8 (C),
133.4 (CH), 134.4 (CH), 136.2 (C), 150.7 (C), 154.1 (C),
155.8 (C), 192.0 (C). HRMS (ESI, IT-TOF) calculated for
C23H21N2O3
+: 373.1547; found: 373.1596.
2.1.2. 13-(Benzo[d][1,3]dioxol-5-yl)-3,3-dimethyl-2,3,4,13-
tetrahydro-1H-indazolo[1,2-b]phthalazine-1,6,11-trione (8)
(Veeranarayana Reddy et al., 2012)
Yellow solid. mp: 256–257 C. IR (KBr) (mmax/cm1): 2962,
2898, 1662, 1624, 1490, 1364, 1314, 1268, 1244, 1100, 1034,
924, 788, 700. 1H NMR (200 MHz, CDCl3): d 1.21 (s, 3H,
CH3), 1.22 (s, 3H, CH3), 2.34 (bs, 2H, CH2), 3.22 (d, 1H,Please cite this article in press as: Rego, Y.F. et al., Phthalazine-triones: Calix[4]arene-
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(s, 2H, CH2), 6.36 (s, 1H, CH), 6.75 (d, 1H, J= 8.0 Hz,
ArH), 6.84 (s, 1H, ArH), 6.94 (d, 1H, J= 8.0 Hz, ArH),
7.76–7.95 (m, 2H, ArH), 8.19–8.42 (m, 2H, ArH); 13C NMR
(50 MHz, CDCl3): d 28.5 (CH3), 28.6 (CH3), 34.6 (C), 38.0
(CH2), 50.9 (CH2), 64.7 (CH), 101.2 (CH2), 107.4 (CH), 108.4
(CH), 118.4 (C), 121.2 (CH), 127.6 (CH), 127.9 (CH), 128.9
(C), 129.1 (C), 130.1 (C), 133.5 (CH), 134.5 (CH), 147.9 (C),
150.8 (C), 154.3 (C), 156.0 (C), 192.1 (C). HRMS (ESI, IT-
TOF) calculated for C24H21N2O5
+: 417.1445; found: 417.1442.
2.1.3. 13-(4-Chlorophenyl)-3,3-dimethyl-2,3,4,13-tetrahydro-
1H-indazolo[1,2-b]phthalazine-1,6,11-trione (9) (Sayyafi
et al., 2008)
Yellow solid. mp: 227–229 C. IR (KBr) (mmax/cm1): 3166,
3032, 2958, 2932, 2894, 1654, 1624, 1492, 1468, 1362, 1312,
1268, 1148, 1106, 1090, 1014, 840, 794, 698, 530. 1H NMR
(200 MHz, CDCl3): d 1.20 (bs, 6H, 2x CH3), 2.33 (bs, 2H,
CH2), 3.23 (d, 1H, J= 19.0 Hz, CH2), 3.41 (d, 1H,
J= 19.0 Hz, CH2), 6.41 (s, 1H, CH), 7.29 (d, 2H,
J= 8.5 Hz, ArH), 7.37 (d, 2H, J= 8.5 Hz, ArH), 7.78–7.90
(m, 2H, ArH), 8.18–8.41 (m, 2H, ArH); 13C NMR (50 MHz,
CDCl3): d 28.3 (CH3), 28.6 (CH3), 34.6 (C), 37.9 (CH2), 50.7
(CH2), 64.2 (CH), 117.9 (C), 127.6 (CH), 127.9 (CH), 128.4
(CH), 128.7 (C), 128.8 (C, CH), 133.6 (CH), 134.4 (C), 134.5
(CH), 134.8 (C), 150.1 (C), 154.3 (C), 155.9 (C), 192.0 (C).
HRMS (ESI, IT-TOF) calculated for C23H20ClN2O3
+:
407.1157; found: 407.1144.
2.1.4. 13-(4-Fluorophenyl)-3,3-dimethyl-2,3,4,13-tetrahydro-
1H-indazolo[1,2-b]phthalazine-1,6,11-trione (10) (Sayyafi
et al., 2008)
Yellow solid. mp: 196–198 C. IR (KBr) (mmax/cm1): 3070,
2960, 2926, 2878, 1666, 1628, 1602, 1508, 1468, 1420, 1360,
1314, 1268, 1220, 1144, 1098, 1080, 1028, 850, 798, 702, 528.
1H NMR (200 MHz, CDCl3): d 1.21 (bs, 6H, 2x CH3), 2.34
(bs, 2H, CH2), 3.23 (d, 1H, J= 19.2 Hz, CH2), 3.42 (d, 1H,
J= 19.2 Hz, CH2), 6.43 (s, 1H, CH), 6.92–7.11 (m, 2H,
ArH), 7.32–7.49 (m, 2H, ArH), 7.78–7.93 (m, 2H, ArH),
8.20–8.42 (m, 2H, ArH); 13C NMR (50 MHz, CDCl3): d 28.4
(CH3), 28.6 (CH3), 34.6 (C), 38.0 (CH2), 50.9 (CH2), 64.2
(CH), 115.7 (d, JC–F = 21.8 Hz, CH), 118.2 (C),127.7 (CH),
128.0 (CH), 128.9 (C), 129.0 (d, JC–F = 8.6 Hz, CH), 132.2
(C), 133.6 (CH), 134.6 (CH), 151.0 (C), 154.3 (C), 156.0 (C),
192.2 (C). HRMS (ESI, IT-TOF) calculated for C23H20FN2-
O3
+: 391.1452; found: 391.1466.
Crystals suitable for single-crystal X-ray diffractometry
were obtained from slow evaporation of a saturated methano-
lic solution of the product.
2.1.5. 13-(4-Nitrophenyl)-3,3-dimethyl-2,3,4,13-tetrahydro-1H-
indazolo[1,2-b]phthalazine-1,6,11-trione (11) (Sayyafi et al.,
2008)
Yellow solid. mp: 205–206 C. IR (KBr) (mmax/cm1): 3076,
2970, 2956, 1694, 1660, 1618, 1522, 1470, 1366, 1312, 1276,
1256, 1146, 1018, 856, 792, 696, 578. 1H NMR (200 MHz,
CDCl3): d 1.20 (s, 3H, CH3), 1.22 (s, 3H, CH3), 2.34 (bs, 2H,
CH2), 3.26 (d, 1H, J= 18.8 Hz, CH2), 3.43 (d, 1H,
J= 18.8 Hz, CH2), 6.51 (s, 1H, CH), 7.61 (d, 2H,
J= 8.0 Hz, ArH), 7.82–8.00 (m, 2H, ArH), 8.12–8.50assisted synthesis using green solvents and their anticancer activities against human
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4 Y.F. Rego et al.(m, 4H, ArH); 13C NMR (50 MHz, CDCl3): d 28.3 (CH3), 28.6
(CH3), 34.7 (C), 38.0 (CH2), 50.7 (CH2), 64.1 (CH), 117.2 (C),
124.0 (CH), 127.7 (CH), 128.0 (CH), 128.2 (CH), 128.5
(C), 128.9 (C), 133.9 (CH), 134.8 (CH), 143.4 (C), 147.8 (C),
151.7 (C), 154.5 (C), 155.9 (C), 192.1 (C). HRMS (ESI, IT-
TOF) calculated for C23H20N3O5
+: 418.1397; found: 418.1388.
2.1.6. 13-(3-Hydroxyphenyl)-3,3-dimethyl-2,3,4,13-tetrahydro-
1H-indazolo[1,2-b]phthalazine-1,6,11-trione (12) (Ghorbani-
Vaghei et al., 2011)
White solid. mp: 260–261 C. IR (KBr) (mmax/cm1): 3356,
3116, 2952, 2872, 1662, 1630, 1592, 1470, 1432, 1360, 1314,
1288, 1266, 1234, 1144, 1102, 1084, 784, 700, 686, 532. 1H
NMR (200 MHz, DMSO-d6): d 1.11 (s, 3H, CH3), 1.12 (s,
3H, CH3), 2.27 (bs, 2H, CH2), 3.16 (dd, 1H, J= 18.8 Hz,
J= 2.1 Hz, CH2), 3,27–3.37 (m, 1H, CH2), 6.18 (s, 1H, CH),
6.62–6.68 (m, 1H, ArH), 6.79–6.85 (m, 2H, ArH), 7.08 (t,
1H, J= 8.1 Hz, ArH), 7.93–8.01 (m, 2H, ArH), 8.08–8.15
(m, 1H, ArH), 8.23–8.30 (m, 1H, ArH), 9.39 (s, 1H, OH);
13C NMR (75 MHz, DMSO-d6): d 27.8 (CH3), 28.0 (CH3),
34.3 (C), 37.2 (CH2), 50.3 (CH2), 64.2 (CH), 114.4 (CH),
114.9 (CH), 117.6 (C), 117.8 (CH), 126.8 (CH), 127.6 (CH),
128.7 (C), 128.9 (C), 129.1 (CH), 133.7 (CH), 134.6
(CH),138.8 (C), 151.0 (C), 153.7 (C), 155.3 (C),157.2 (C),
191.8 (C). HRMS (ESI, IT-TOF) calculated for
C23H21N2O4
+: 389.1496; found: 389.1472.
2.1.7. 13-(4-Cyanophenyl)-3,3-dimethyl-2,3,4,13-tetrahydro-
1H-indazolo[1,2-b]phthalazine-1,6,11-trione (13)
(Hasaninejed et al., 2012)
Yellow solid. mp: 213–215 C. IR (KBr) (mmax/cm1): 3130,
3040, 2958, 2932, 2230, 1654, 1620, 1502, 1468, 1390, 1362,
1312, 1270, 1150, 1106, 1026, 844, 792, 700, 558, 498. 1H
NMR (200 MHz, CDCl3): d 1.19 (s, 3H, CH3), 1.22 (s, 3H,
CH3), 2.34 (bs, 2H, CH2), 3.25 (d, 1H, J= 19.2 Hz, CH2),
3.41 (d, 1H, J= 19.2 Hz, CH2), 6.45 (s, 1H, CH), 7.55
(d, 2H, J= 8.1 Hz, ArH), 7.63 (d, 2H, J= 8.1 Hz, ArH),
7.81–7.96 (m, 2H, ArH), 8.19–8.43 (m, 2H, ArH); 13C NMR
(50 MHz, CDCl3): d 28.3 (CH3), 28.6 (CH3), 34.6 (C), 37.9
(CH2), 50.7 (CH2), 64.3 (CH), 112.3 (C), 117.2 (C), 118.3
(C), 127.6 (CH), 127.8 (CH), 128.1 (CH), 128.5 (C), 128.8
(C), 132.5 (CH), 133.8 (CH), 134.7 (CH), 141.5 (C), 151.5
(C), 154.4 (C), 155.8 (C), 192.0 (C). HRMS (ESI, IT-TOF) cal-
culated for C24H20N3O3
+: 398.1499; found: 398.1471.
2.1.8. 13-(3-Methoxyphenyl)-3,3-dimethyl-2,3,4,13-tetrahydro-
1H-indazolo[1,2-b]phthalazine -1,6,11-trione (14)
(Hasaninejed et al., 2012)
Yellow solid. mp: 221–222 C. IR (KBr) (mmax/cm1): 3030,
3022, 2971, 2937, 1654, 1600, 1502, 1372, 1221, 1180, 1031,
744, 535, 496. 1H NMR (200 MHz, CDCl3): d 1.21 (bs, 6H,
2x CH3), 2.33 (bs, 2H, CH2), 3,22 (d, 1H, J= 19.3 Hz,
CH2), 3,41 (d, 1H, J= 19.3 Hz, CH2), 3.78 (s, 3H, OCH3),
6.41 (s, 1H, CH), 6.82 (d, 1H, J= 8.0 Hz, ArH), 6.95
(s, 1H, ArH), 7.00 (d, 1H, J= 8.0 Hz, ArH), 7.25 (t, 1H,
J= 8.0 Hz, ArH), 7.77–7.94 (m, 2H, ArH), 8.20–8.43 (m,
2H, ArH); 13C NMR (50 MHz, CDCl3): d 28.4 (CH3), 28.6
(CH3), 34.6 (C), 38.0 (CH2), 50.9 (CH2), 55.2 (CH3), 64.7
(CH), 113.1 (CH), 113.8 (CH), 118.5 (C), 119.4 (CH), 127.7
(CH), 127.9 (CH), 128.9 (C), 129.0 (C), 129.7 (CH), 133.5Please cite this article in press as: Rego, Y.F. et al., Phthalazine-triones: Calix[4]arene-
cancer cells. Arabian Journal of Chemistry (2016), http://dx.doi.org/10.1016/j.arabjc.2(CH), 134.5 (CH), 137.9 (C), 150.8 (C), 154.2 (C), 156.0 (C),
159.7 (C), 192.1 (C). HRMS (ESI, IT-TOF) calculated for
C24H23N2O4
+: 403.1652; found: 403.1626.2.1.9. 13-(4-Hydroxy-3,5-dimethoxyphenyl)-3,3-dimethyl-
2,3,4,13-tetrahydro-1H-indazolo[1,2-b]phthalazine-1,6,11-
trione (15)
Yellow solid. mp: 210–212 C. IR (KBr) (mmax/cm1): 3510,
3168, 3018, 2962, 1656, 1624, 1518, 1492, 1466, 1432, 1362,
1314, 1266, 1218, 1146, 1112, 1082, 826, 792, 700, 628. 1H
NMR (200 MHz, CDCl3): d 1.24 (bs, 6H, 2x CH3), 2.36 (bs,
2H, CH2), 3.21 (d, 1H, J= 19.1 Hz, CH2), 3.47 (d, 1H,
J= 19.1 Hz, CH2), 3.85 (bs, 6H, 2x OCH3), 5.68 (bs, 1H,
OH), 6.38 (s, 1H, CH), 6.65 (s, 2H, ArH), 7.79–7.95 (m, 2H,
ArH), 8.21–8.43 (m, 2H, ArH); 13C NMR (50 MHz, CDCl3):
d 28.0 (CH3), 28.9 (CH3), 34.5 (C), 38.0 (CH2), 50.8 (CH2),
56.3 (2x CH3), 65.0 (CH), 104.4 (CH), 118.3 (C), 127.2 (C),
127.6 (CH), 127.9 (CH), 128.8 (C), 129.0 (C), 133.5 (CH),
134.5 (CH), 136.2 (C), 147.0 (C), 150.7 (C), 154.4 (C), 156.1
(C), 192.2 (C). HRMS (ESI, IT-TOF) calculated for
C25H25N2O6
+: 449.1707; found: 449.1691.2.1.10. 3,3-Dimethyl-13-(4-(trifluoromethyl)phenyl)-2,3,4,13-
tetrahydro-1H-indazolo[1,2-b]phthalazine-1,6,11-trione (16)
(Wang et al., 2010)
Yellow solid. mp: 248–250 C. IR (KBr) (mmax/cm1): 2960,
2934, 2874, 1658, 1624, 1468, 1424, 1360, 1310, 1266, 1162,
1130, 1066, 854, 702. 1H NMR (200 MHz, CDCl3): d 1.20
(s, 3H, CH3), 1.22 (s, 3H, CH3), 2.34 (bs, 2H, CH2), 3.25
(dd, 1H, J= 19.2 Hz, J= 2.2 Hz, CH2), 3.41 (dd, 1H,
J= 19.2 Hz, J= 1.0 Hz, CH2), 6.49 (s, 1H, CH), 7.54
(d, 2H, J= 8.4 Hz, ArH), 7.61 (d, 2H, J= 8.4 Hz, ArH),
7.84–7.93 (m, 2H, ArH), 8.22–8.42 (m, 2H, ArH); 13C NMR
(50 MHz, CDCl3): d 28.4 (CH3), 28.7 (CH3), 34.7 (C), 38.0
(CH2), 50.8 (CH2), 64.4 (CH), 117.8 (C), 125.8
(q, J= 3.9 Hz, CH), 127.4 (CH), 127.8 (CH), 128.1 (CH),
128.8 (C), 128.9 (C), 130.7 (q, J= 32.5 Hz, C), 133.8 (CH),
134.7 (CH), 140.3 (C), 151.3 (C), 154.4 (C), 156.0 (C), 192.1
(C). HRMS (ESI, IT-TOF) calculated for C24H20F3N2O3
+:
441.1421; found: 441.1441.2.1.11. 3,3-Dimethyl-13-(4-(methylthio)phenyl)-2,3,4,13-
tetrahydro-1H-indazolo[1,2-b]phthalazine-1,6,11-trione (17)
(Ghorbani-Vaghei et al., 2011)
Yellow solid. mp: 216–218 C. IR (KBr) (mmax/cm1): 3024,
2960, 2946, 2924, 1656, 1630, 1466, 1360, 1312, 1268, 1148,
1104, 1092, 704. 1H NMR (200 MHz, CDCl3): d 1.20
(bs, 6H, 2x CH3), 2.33 (bs, 2H, CH2), 2.42 (s, 3H, CH3),
3.22 (dd, 1H, J= 19.1 Hz, J= 1.8 Hz, CH2), 3.42 (d, 1H,
J= 19.1 Hz, CH2), 6.40 (s, 1H, CH), 7.19 (d, 2H,
J= 8.3 Hz, ArH), 7.33 (d, 2H, J= 8.3 Hz, ArH), 7.77–7.89
(m, 2H, ArH), 8.19–8.40 (m, 2H, ArH); 13C NMR (50 MHz,
CDCl3): d 15.6 (CH3), 28.4 (CH3), 28.6 (CH3), 34.5 (C), 38.1
(CH2), 51.0 (CH2), 64.5 (CH), 118.4 (C), 126.1 (CH), 127.5
(CH), 127.6 (CH), 127.9 (CH), 129.0 (C), 129.1 (C), 133.2
(C), 133.4 (CH), 134.4 (CH), 139.2 (C), 150.8 (C), 154.3 (C),
156.0 (C), 191.9 (C). HRMS (ESI, IT-TOF) calculated for C24
H23N2O3S
+: 419.1424; found: 419.1424.assisted synthesis using green solvents and their anticancer activities against human
016.04.007
Calix[4]arene-assisted synthesis 52.1.12. 3,3-Dimethyl-13-propyl-2,3,4,13-tetrahydro-1H-indazolo
[1,2-b]phthalazine-1,6,11-trione (18) (Ghorbani-Vaghei et al.,
2011)
Yellow solid. mp: 186–187 C. IR (KBr) (mmax/cm1): 3158,
3016, 1646, 1622, 1515, 1490, 1456, 1422, 1382, 1310, 1260,
1141, 1110, 1081, 824, 790, 666. 1H NMR (200 MHz, CDCl3):
d 0.87 (t, 3H, J= 7.2 Hz, CH3), 1.06–1.30 (m, 8H, CH2, 2x
CH3), 1.90–2.53 (m, 4H, 2x CH2), 3.13 (d, 1H, J= 19.3 Hz,
CH2), 3.34 (d, 1H, J= 19.3 Hz, CH2), 5.70 (s, 1H, CH),
7.79–7.97 (m, 2H, ArH), 8.28–8.42 (m, 2H, ArH); 13C NMR
(50 MHz, CDCl3): d 13.7 (CH3), 16.7 (CH2), 28.5 (CH3),
28.7 (CH3), 31.5 (CH2), 34.5 (C), 38.0 (CH2), 51.0 (CH2),
62.8 (CH), 117.3 (C), 127.5 (CH), 127.9 (CH), 128.9 (C),
129.0 (C), 133.4 (CH), 134.5 (CH), 151.6 (C), 154.7 (C),
156.1 (C), 193.1 (C). HRMS (ESI, IT-TOF) calculated for
C20H23N2O3
+: 339.1703; found: 339.1691.
2.1.13. 13-Butyl-3,3-dimethyl-2,3,4,13-tetrahydro-1H-indazolo
[1,2-b]phthalazine-1,6,11-trione (19)
Yellow solid. mp: 146–148 C. IR (KBr) (mmax/cm1): 3078,
2962, 2928, 2856, 1654, 1626, 1468, 1434, 1366, 1294, 1274,
1152, 1086, 788, 696. 1H NMR (200 MHz, CDCl3): d 0.81
(t, 3H, J= 7.1 Hz, CH3), 1.01–1.37 (m, 10H, 2x CH2, 2x
CH3), 2.01–2.55 (m, 4H, 2x CH2), 3.13 (dd, 1H, J= 19.2 Hz,
J= 2.3 Hz, CH2), 3.35 (d, 1H, J= 19.2 Hz, CH2), 5.70 (s,
1H, CH), 7.76–7.96 (m, 2H, ArH), 8.23–8.43 (m, 2H, ArH);
13C NMR (50 MHz, CDCl3): d 13.8 (CH3), 22.3 (CH2), 25.5
(CH2), 28.4 (CH3), 28.7 (CH3), 29.3 (CH2), 34.4 (C), 38.1
(CH2), 51.1 (CH2), 62.9 (CH), 117.4 (C), 127.5 (CH), 127.8
(CH), 129.0 (C), 129.1 (C), 133.3 (CH), 134.3 (CH), 151.5 (C),Table 1 Optimization of the reaction conditions for the synthesis o
CHO
O O
NH
NH
O
O
Entry Catalyst (mol%) Solvent
1 – Ethanol
2 5 (2.5) Ethanol
3 5 (2.0) Ethanol
4 5 (1.5) Ethanol
5 5 (1.0) Ethanol
6 5 (0.5) Ethanol
7 PHSAc (6.0) Ethanol
8 PHSA (9.0) Ethanol
9 5 (1.5) Ethanol
10 5 (1.5) Dimethyl carbonate
11 5 (1.5) Diethyl carbonate
12 5 (1.5) Ethyl lactate
a Reagents and conditions: benzaldehyde/5,5-dimethylcyclohexane-1,3-
irradiation.
b Isolated yields.
c PHSA= p-hydroxybenzenesulfonic acid.
Please cite this article in press as: Rego, Y.F. et al., Phthalazine-triones: Calix[4]arene-
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calculated for C21H25N2O3
+: 353.1860; found: 353.1797.
2.1.14. 3,3-Dimethyl-2,3,4,13-tetrahydro-1H-indazolo[1, 2-b]
phthalazine-1,6,11-trione (20)
Yellow solid. mp: 150–152 C. IR (KBr) (mmax/cm1): 3168,
3022, 2958, 2892, 1656, 1494, 1360, 1270, 1082, 848, 792,
700. 1H NMR (200 MHz, CDCl3): d 1.18 (br, 6H, 2x CH3),
2.37 (bs, 2H, CH2), 3.20 (br, 2H, CH2), 4.93 (bs, 2H, CH2),
7.73–7.96 (m, 2H, ArH), 8.22–8.39 (m, 2H, ArH); 13C NMR
(50 MHz, CDCl3): d 28.5 (2x CH3), 34.6 (C), 38.0 (CH2),
49.5 (CH2), 50.7 (CH2), 114.9 (C), 127.4 (CH), 127.9 (CH),
128.6 (C), 129.0 (C), 133.4 (CH), 134.3 (CH), 152.3 (C),
154.5 (C), 155.9 (C), 192.7 (C). HRMS (ESI, IT-TOF) calcu-
lated for C17H17N2O3
+: 297.1234; found: 297.1506.
2.2. Antiproliferative assay
Human tumor cell lines U251 (glioma), MCF7 (breast) NCI-
ADR/RES (multiple drug-resistant ovarian), 786-0 (renal),
NCI-H460 (lung, non-small cells), PC-3 (prostate), OVCAR-
03 (ovarian) HT-29 (colon) and K562 (leukemia) were kindly
provided by the Frederick Cancer Research & Development
Center, National Cancer Institute (Frederick, MA, USA).
Stock cultures were grown in RPMI 1640 (GIBCO BRL, Life
Technologies) supplemented with 5% of fetal bovine serum
and penicillin (ﬁnal concentration of 1 mg/mL) and strepto-
mycin (ﬁnal concentration of 200 U/mL). Cells in 96-well
plates (100 lL cells/well) were exposed to phthalazine-triones
(0.25–250 lg/mL) for 48 h at 37 C and 5% of CO2. Afterwardf phthalazine-trione 7a.
catalyst
solvent
N
N
O
O
O
7
Temperature (C) Time (min) Yield (%)b
Reﬂux 10 0
Reﬂux 10 41
Reﬂux 10 22
Reﬂux 10 75
Reﬂux 10 45
Reﬂux 10 39
Reﬂux 10 12
Reﬂux 10 60
Reﬂux 5 35
Reﬂux 10 5
Reﬂux 10 6
130 10 81
dione/phthalhydrazide (molar ratio = 1.5:1.2:1.0), under microwave
assisted synthesis using green solvents and their anticancer activities against human
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6 Y.F. Rego et al.cells were ﬁxed with 50% trichloroacetic acid, submitted to sul-
forhodamine B assay for cell proliferation quantiﬁcation at
540 nm (Monks et al., 1991). The concentration of compound
that inhibits cell growth by 50% (GI50) was determined
through non-linear regression analysis using software ORI-
GIN 7.5 (OriginLab Corporation). Doxorubicin was used as
a reference drug.3. Results and discussion
3.1. Synthesis of phthalazine-triones
Sulfonic acid calix[n]arenes have proven to be efﬁcient cata-
lysts in different types of organic reactions (Fernandes et al.,
2012; Natalino et al., 2014; Liu et al., 2008; Shimizu et al.,
2006). Recently, we demonstrated that these macrocycles are
effective in promoting synthesis of xanthenones by multicom-
ponent reactions (da Silva et al., 2015). Thus, in the present
study, we evaluated the efﬁciency of p-sulfonic acid calix[4]
arene 5 in the synthesis of phthalazine-triones.
A preliminary investigation aiming to optimize the reaction
conditions was performed. For a model reaction, benzalde-
hyde, 5,5-dimethylcyclohexane-1,3-dione and phthalhydrazide
were employed (Table 1). The reactions were performed in a
DiscoverCem reactor for a period of 10 min using ethanol
as the solvent. Initially, we evaluated the catalytic activity of
p-sulfonic acid calix[4]arene (5) in promoting the reaction. This
catalyst was tested in ratios ranging from 2.5 to 0.5 mol%
(Table 1, entries 2–6). The best yield was obtained when 5Table 2 Use of different aldehydes in the synthesis of phthalazine-
R
CHO
O O
NH
NH
O
O
Entry R
1 Phenyl
2 3,4-OCH2O-phenyl
3 4-Cl-phenyl
4 4-F-phenyl
5 4-NO2-phenyl
6 3-OH-phenyl
7 4-CN-phenyl
8 3-OCH3-phenyl
9 3,5-OCH3, 4-OH-phenyl
10 4-CF3-phenyl
11b 4-SCH3-phenyl
12b n-propyl
13b n-butyl
14b H
a Reagents and conditions: aldehyde/5,5-dimethylcyclohexane-1,3-dione
at 130 C under microwave irradiation.
b These reactions were carried out at 85 C under microwave irradiatio
Please cite this article in press as: Rego, Y.F. et al., Phthalazine-triones: Calix[4]arene-
cancer cells. Arabian Journal of Chemistry (2016), http://dx.doi.org/10.1016/j.arabjc.2was used at a concentration of 1.5 mol% (Table 1, entry 4).
Interestingly, the yields decreased with an increase in the molar
ratio of the catalyst (Table 1, entries 2 and 3). The use of p-
sulfonic acid calix[6]arene (6) as the catalyst furnished the
desired products in low yields (<40%) (data not shown). To
explore the role of the spatial arrangement imposed by the
calix[4]arene 5 on the efﬁciency of the catalysis process, we
used p-hydroxybenzenesulfonic acid (PHSA) as a catalyst.
Because each molecule of p-sulfonic acid calix[4]arene corre-
sponds to four units of PHSA, this catalyst was used at a con-
centration of 6.0 mol% (Table 1, entry 7). At this
concentration, PHSA led to the formation of phthalazine-
trione 7 in only a 12% yield. Even at a concentration of
9.0 mol%, PHSA was still less effective than p-sulfonic acid
calix[4]arene (Table 1, entry 8). These results suggest that the
spatial organization of the macrocycle is important for the cat-
alytic activity. No product formation was observed in the reac-
tion carried out without any catalyst under the tested
experimental conditions (Table 1, entry 1).
Once the optimal concentration of p-sulfonic acid calix[4]
arene was obtained, we evaluated the effect of reducing the
reaction time. Thus, a new test reaction was carried out for a
period of 5 min. However, the reduction in the reaction time
led to a signiﬁcant decrease in the yield (Table 1, entry 9).
The promising results obtained with calix[4]arene 5
prompted us to further investigate the effect of solvents in
the synthesis of phthalazine-trione 7 catalyzed by this macro-
cyclic compound. Dimethyl carbonate, diethyl carbonate,
and ethyl lactate were evaluated. Dimethyl and diethyl carbon-
ate furnished 7 in low yields (5% and 6%, respectively)trione derivativesa.
5 (1.5 mol %)
ethyl lactate
N
N
O
O
O
R
(7-20)
Compound Yield (%)b
7 81
8 51
9 85
10 83
11 83
12 67
13 87
14 75
15 61
16 94
17 31
18 30
19 35
20 11
/phthalhydrazide (molar ratio = 1.5:1.2:1.0) using 1 mL ethyl lactate
n.
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Table 3 Crystal data and structural reﬁnement results for 10.
CCDC number 1,021,277
Empirical formula C23H19FN2O3
Molecular weight (g mol1) 390.40
Crystal system Monoclinic
Space group P21/n
Unit cell dimensions a (A˚) 8.5083(2)
b (A˚) 20.3729(4)
c (A˚) 11.3768(3)
a= c () 90
b () 111.220(3)
V (A˚3) 1838.33(7)
Z 4
Density calculated (g cm3) 1.411
Absorption coeﬃcient (mm1) 0.101
F(000) 816
Crystal size (mm3) 0.64  0.59  0.25
h range for data collection () 2.00–26.37
Index ranges 10 6 h 6 10
25 6 k 6 25
14 6 l 6 14
Reﬂections collected 36,936
Independent reﬂections 3762 [R(int) = 0.0351]
Completeness to h= 26.37 (%) 100.0
Max. and min. transmission 1.00000 and 0.83326
Data/restraints/parameters 3762/0/264
Goodness-of-ﬁt on F2 1.059
Final R indices [I> 2r(I)] R1 = 0.0362, wR2 = 0.0902
R indices (all data) R1 = 0.0409, wR2 = 0.0938
Largest diﬀ. peak and hole (eA˚3) 0.235 and 0.314
Calix[4]arene-assisted synthesis 7(Table 1, entries 10 and 11). The best yield, 81%, was achieved
using ethyl lactate as the solvent (Table 1, entry 12). Reactions
carried out without solvents furnished phthalazine-trione 7 in
yields lower than 40% (data not shown).
After establishing the best solvent, the scope of this proto-
col was further investigated. Aliphatic and aromatic aldehydes
bearing electron-donating or electron-withdrawing groups
were employed in the synthesis of a series of phthalazine-
trione derivatives, and the expected products were obtained,
mainly, in good to moderate yields (Table 2).
In general, aromatic aldehydes led to good yields, except
for piperonal and 4-(methylthio)benzaldehyde (Table 2, entries
2 and 11, respectively). Aldehydes with electron-withdrawing
groups led to higher yields (83–94%) than do those with
electron-donating groups. However, non-aromatic aldehydes
were less reactive than aromatic aldehydes and afforded only
low yields (Table 2, entries 12–14).
Once synthesized, the structural features of the compounds
were determined from the corresponding IR, NMR, and ESI-
HRMS data. Crystals of 10 were formed, and its crystal struc-
ture was determined using single-crystal X-ray diffractometry.
The atom arrangements and atom numbering scheme for 10
are shown in Fig. 3 while the crystal data and reﬁnement
results are listed in Table 3.
Phthalazine-trione 10 crystallized in the monoclinic space
group P21/n with one independent molecule in the asymmetric
unit. Although the molecule shown in Fig. 3 has a chiral center
located on atom C15, the compound crystallized as a racemate
because it crystallizes in a centrosymmetric space group. TheFigure 3 Molecular plot of 10 showing the labeling scheme of the non-H atoms and their displacement ellipsoids at a 50% probability
level. The hydrogen atoms are shown as circles of arbitrary radii.
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Table 4 Concentration of phthalazine-triones (GI50 in lg/mL) that elicit cancer cells
a growth inhibition by 50%.
Compound Cell Line
U251 MCF7 NCI-ADR/RES 786-0 NCI-H460 PC-3 OVCAR-3 HT-29 K-562 HaCaT
7 115.1 >250 >250 131.0 >250 17.5 136.6 >250 >250 16.8
8 >250 >250 >250 140.9 >250 >250 >250 >250 >250 >250
9 >250 >250 >250 >250 >250 204.7 >250 >250 >250 >250
10 90.3 243.5 41.5 74.0 83.7 29.2 26.8 >250 175.1 201.4
11 >250 >250 >250 >250 >250 >250 >250 >250 >250 >250
12 27.0 21.3 9.1 39.6 40.5 23.8 15.6 70.7 54.1 25.4
13 >250 225.4 129.8 247.1 >250 >250 51.0 >250 >250 152.1
14 139.8 101.4 >250 79.4 >250 52.2 95.2 >250 >250 >250
15 147.5 >250 210.0 128.8 >250 203.7 72.4 >250 >250 >250
16 >250 >250 >250 >250 >250 >250 93.5 >250 7.4 >250
17 127.8 >250 >250 58.9 >250 >250 119.9 >250 28.6 >250
18 48.8 132.9 10.5 42.1 122.2 26.2 23.5 60.5 41.4 43.2
19 >250 >250 51.7 >250 >250 138.8 >250 >250 2.6 >250
20 171.4 124.0 >250 >250 >250 5.3 186.2 >250 9.4 >250
Doxb 0.03 0.06 0.05 0.03 0.01 0.03 0.24 0.08 0.03 0.2
a U251, glioma cells; MCF7, breast cancer cells; NCI-ADR/RES, multiple drug-resistant ovarian cancer cells; 786-0, renal cancer cells; NCI-
H460, non-small lung cancer cells; PC-3, prostate cancer cells; OVCAR-03, ovarian cancer cells; HT-29, colon cancer cells; K562, leukemia.
b Dox, reference drug doxorubicin.
8 Y.F. Rego et al.geometrical parameters for the indazolophthalazine-1,6,
11-trione skeleton of 10 are very similar to those reported
for 13-(4-bromophenyl)-3,3-dimethyl-2,3,4,13-tetrahydro-1H-
indazolo[1,2-b]phthalazine-1,6,11-trione (Sayyaﬁ et al., 2008).
3.2. Antiproliferative activities
The effect of synthesized phthalazine-triones (0.25–250 lg/mL)
on glioma (U251), breast (MCF-7), adriamycin-resistant
ovarian cancer (NCI-ADR/RES), kidney cancer (786-0), lung
non-small cancer (NCI-H460), prostate cancer (PC-3), ovarian
cancer (OVCAR-03), colon cancer (HT-29) and leukemia
(K562) cells was also studied. Cell proliferation was determined
by the sulforhodamine B method using doxorubicin (Dox) as a
positive control. The concentration of phthalazine-triones that
elicited the inhibition of cell growth by 50% (GI50) is summa-
rized in Table 4. The selectivity index (SI), herein is deﬁned as
the ratio of the GI50 of pure compound in HaCaT cell line to
the GI50 of the same pure compound in a cancer cell line, for
the most promising compounds and doxorubicin.
Compounds 12 and 18 were the most active compounds
against NCI-ADR/RES cell line (Table 4) with GI50 values
lower than 15 lg/mL. Compound 20 had the most promising
activity against PC-3 cancer cells, with GI50 value of 5.3 lg/
mL (Table 4) and SI of over 47, 15-fold more than required
to deﬁne a highly selective compound (Prayong et al., 2008).
For K562 cells, compounds 16, 19 and 20 were active with
GI50 values of 7.4, 2.6 and 9.4 lg/mL (Table 4) and SI greater
than 33.8, 96.2 and 26.6, respectively. It is noteworthy that
doxorubicin’s SI for PC-3 and K562 cell lineages was equal
to 0.2, demonstrating no differentiation of normal cells and
cancerous cells.
Among the cell lines tested K562 was the most sensitive,
and three phthalazine-triones were active against these cells.
For U251, MCF7, 786-0, NCI-H460, OVCAR-3 and HT29
cell lines, none of the compounds tested proved to be active.
Compound 20 was the only active against more than one
strain. Overall, the potency of phthalazine-triones adducts
was dependent on the histological origin of cancer cells.Please cite this article in press as: Rego, Y.F. et al., Phthalazine-triones: Calix[4]arene-
cancer cells. Arabian Journal of Chemistry (2016), http://dx.doi.org/10.1016/j.arabjc.24. Conclusion
A new and efﬁcient green methodology for obtaining 2H-indazolo[2,1-
b]phthalazine-trione derivatives was developed using p-sulfonic acid
calix[4]arene as a catalyst and ethyl lactate as the solvent. Fourteen
compounds were obtained in moderate to good yields in only 10 min
of reaction time. This procedure is of great interest because it allows
the synthesis of compounds of biological and technological interest
through an environmentally friendly methodology.
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